Researchers reported advances in in vivo CAR-neutrophil engineering aimed at glioma treatment, tackling a longstanding hurdle in cell-based therapies: direct genetic programming of neutrophils. Because neutrophils are abundant immune cells that can interact with the tumor microenvironment, the approach targets the engineering challenge rather than relying solely on ex vivo cell manufacturing workflows. The development centers on techniques that enable functional CAR expression within neutrophil biology in vivo, with the intent to generate therapeutic anti-tumor activity inside the tumor setting. For glioma, which remains notoriously difficult to treat with conventional immunotherapies, CAR-neutrophils are positioned as a potential way to expand the immune effector toolkit. The report adds to a broader trend toward platformized in vivo or rapidly deployable cell engineering, with glioma as a high-bar clinical benchmark.